Efficacy and tolerability of aripiprazole in outpatients with schizophrenia or schizoaffective disorder

被引：0
|
作者：
Shin, D. [1 ]
机构：
[1] Hongseong Med Ctr, Hongseong, South Korea
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2009年 / 19卷
关键词：
D O I：
10.1016/S0924-977X(09)70815-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S515 / S515
页数：1
相关论文
共 50 条
  • [41] The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia
    Ballús, C
    Quiros, G
    de Flores, T
    de la Torre, J
    Palao, D
    Rojo, L
    Gutiérrez, M
    Casais, L
    Riesgo, Y
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2000, 15 (01) : 43 - 48
  • [42] Tolerability and efficacy of aripiprazole long acting injection (LAI) in bipolar disorder
    Cartas Moreno, F.
    Valverde Barea, M.
    Ortigosa Luque, M. E.
    BIPOLAR DISORDERS, 2016, 18 : 177 - 178
  • [43] A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder
    Takeuchi, Hiroyoshi
    Remington, Gary
    PSYCHOPHARMACOLOGY, 2013, 228 (02) : 175 - 185
  • [44] Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder
    Lambert, Tim J. R.
    EVIDENCE-BASED MENTAL HEALTH, 2009, 12 (02) : 50 - 50
  • [45] Treatment of HIV in Outpatients with Schizophrenia, Schizoaffective Disorder and Bipolar Disease at Two County Clinics
    Murphy, Kaitlyn
    Edelstein, Howard
    Smith, Lance
    Clanon, Kathleen
    Schweitzer, Beth
    Reynolds, Leslie
    Wheeler, Precilla
    COMMUNITY MENTAL HEALTH JOURNAL, 2011, 47 (06) : 668 - 671
  • [46] Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study
    Ryckmans, V.
    Kahn, J. P.
    Modell, S.
    Werner, C.
    McQuade, R. D.
    Kerselaers, W.
    Lissens, J.
    Sanchez, R.
    PHARMACOPSYCHIATRY, 2009, 42 (03) : 114 - 121
  • [47] Treatment of HIV in Outpatients with Schizophrenia, Schizoaffective Disorder and Bipolar Disease at Two County Clinics
    Kaitlyn Murphy
    Howard Edelstein
    Lance Smith
    Kathleen Clanon
    Beth Schweitzer
    Leslie Reynolds
    Precilla Wheeler
    Community Mental Health Journal, 2011, 47 : 668 - 671
  • [48] Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
    Potkin, SG
    Saha, AR
    Kujawa, MJ
    Carson, WH
    Ali, M
    Stock, E
    Stringfellow, J
    Ingenito, G
    Marder, SR
    ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (07) : 681 - 690
  • [49] Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol
    de Oliveira, Irismar Reis
    Elkis, Helio
    Gattaz, Wagner Farid
    Chaves, Ana Cristina
    de Sena, Eduardo Ponde
    de Matos e Souza, Fabio Gomes
    Campos, Joao Alberto
    Bueno, Joao Romildo
    Costa e Silva, Jorge Alberto
    Louza, Mario Rodrigues
    de Abreu, Paulo Belmonte
    CNS SPECTRUMS, 2009, 14 (02) : 93 - 102
  • [50] A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder
    Hiroyoshi Takeuchi
    Gary Remington
    Psychopharmacology, 2013, 228 : 175 - 185
12345